SCHEMBL4853746

SCHEMBL4853746

COC(=O)c1ccc(Cl)cc1Nc1cc(Br)c(OC)cc1N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.55
GAA P10253 2/20 0.49
KDM4E B2RXH2 3/20 0.47
MEN1 O00255 6/20 0.46
KMT2A Q03164 6/20 0.46
KCNMA1 Q12791 1/20 0.43
GRIK1 P39086 1/20 0.41
MAPT P10636 3/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.40
PYGL P06737 1/20 0.40
USP2 O75604 1/20 0.40
PABPC1 P11940 1/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 2/20 0.40
GLA P06280 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
ATM Q13315 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4858020 0.92 GRIK1 (0.51) ABL1GAAKDM4EMEN1KMT2A
SCHEMBL4847961 0.88 ABL1 (0.55) ABL1GAAKDM4EMEN1KMT2A
SCHEMBL27649303 0.85 ABL1 (0.51) ABL1GAAKDM4EMEN1KMT2A
SCHEMBL4853084 0.83 ABL1 (0.49) ABL1GAAKDM4EMEN1KMT2A
SCHEMBL4852986 0.82 ABL1 (0.48) ABL1GAAKDM4EMEN1KMT2A
SCHEMBL4857987 0.81 G6PD (0.47) ABL1KDM4EMEN1KMT2AKCNMA1
SCHEMBL4855887 0.80 ABL1 (0.57) ABL1GAAMEN1KMT2AGRIK1
SCHEMBL4856651 0.80 ABL1 (0.60) ABL1GAAKDM4EMEN1KMT2A
SCHEMBL4854740 0.80 ABL1 (0.60) ABL1GAAKDM4EMEN1KMT2A
SCHEMBL4856000 0.79 G6PD (0.47) ABL1KDM4EMEN1KMT2AKCNMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1606268-B1 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS ABBVIE INC (US) 2015-05-20 EP disclosed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed
US-20040254159-A1 Heterocyclic kinase inhibitors ABBOTT LABORATORIES 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254159-A1 Heterocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K1 ABL1 45/4885GAA 2002/4885KDM4E 1309/4885
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 ABL1 32/4885GAA 1745/4885KDM4E 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.